Pediatric Allergy and Respiratory Unit, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;
Pediatrics Department, Dr. Balmis General University Hospital, Alicante, Spain.
Allergol Immunopathol (Madr). 2022 Sep 1;50(5):148-152. doi: 10.15586/aei.v50i5.642. eCollection 2022.
Drug provocation tests (DPTs) are considered the gold standard for diagnosing beta-lactam allergy. However, positive results tend to be mild and difficult to interpret. This study aimed to describe pediatric patients with a presumedly positive or inconclusive DPT, assess the decision to repeat the DPT, and describe its outcome.
Retrospective review of all presumedly positive or inconclusive DPTs performed in six pediatric allergy clinics from 2017 to 2019. We describe the interpretation of results, focusing on the decision to repeat the DPT and its outcome.
Of 439 children challenged with a beta-lactam, 26 (5.9%) with a presumedly positive or inconclusive result were included in this study. Most were girls (n = 16, 61.5%), and the median age was 5 years (range 1-13). The initial DPT used amoxicillin (n = 13, 50.0%), amoxicillin-clavulanic acid (n = 12, 46.2%), or cefadroxil (n = 1, 3.8%). Reactions were early (n = 11, 42.3 %), delayed (n = 14, 53.8 %), or not registered (n = 1, 3.8 %), but mild in all cases. A second confirmatory DPT was proposed in 19 patients (73.1%) and performed in 17 patients (65.4%). Nine DPTs were performed from 1 day to 4 months after the first DPT, and the remaining eight took place 6 months to 2 years later. Fifteen children tolerated the drug in the second DPT: 88.2% of those reevaluated and 57.5% of the whole study group.
The positive predictive value of DPT may be lower than expected. Given the mildness of observed reactions, a second confirmatory DPT is warranted within a few weeks or months.
药物激发试验(DPT)被认为是诊断β-内酰胺类过敏的金标准。然而,阳性结果往往较为轻微且难以解读。本研究旨在描述疑似阳性或不确定的 DPT 患儿,并评估重复 DPT 的决策及其结果。
回顾性分析 2017 年至 2019 年在 6 家儿科过敏诊所进行的所有疑似阳性或不确定的 DPT。我们描述了结果的解读,重点关注重复 DPT 的决策及其结果。
在接受β-内酰胺类药物挑战的 439 名儿童中,26 名(5.9%)被认为是疑似阳性或不确定的结果,纳入本研究。大多数为女孩(n=16,61.5%),中位年龄为 5 岁(范围 1-13 岁)。初始 DPT 使用阿莫西林(n=13,50.0%)、阿莫西林-克拉维酸(n=12,46.2%)或头孢羟氨苄(n=1,3.8%)。反应为早期(n=11,42.3%)、迟发(n=14,53.8%)或未记录(n=1,3.8%),但均为轻度。19 名患者(73.1%)提出了第二次确认性 DPT,其中 17 名患者(65.4%)进行了 DPT。9 次 DPT 在首次 DPT 后 1 天至 4 个月内进行,其余 8 次则在 6 个月至 2 年内进行。15 名儿童在第二次 DPT 中耐受药物:再次评估的患者中有 88.2%,整个研究组中有 57.5%。
DPT 的阳性预测值可能低于预期。鉴于观察到的反应较为轻微,建议在数周或数月内进行第二次确认性 DPT。